Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1148-1161
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1148
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1148
Table 1 Patient and facility demographics of patients with clinical stage II/III rectal cancer, stratified total mesorectal excision and sphincter preservation
| Local excision (n = 1442) | TME with sphincter preservation (n = 25737) | TME without sphincter preservation (n = 11748) | Total (n = 38927) | P value | |
| Age at diagnosis | < 0.0011 | ||||
| mean ± SD | 66.2 ± 14.13 | 60.3 ± 12.47 | 61.6 ± 12.72 | 60.9 ± 12.67 | |
| Sex | < 0.0012 | ||||
| Male | 787 (54.6%) | 15810 (61.4%) | 7251 (61.7%) | 23848 (61.3%) | |
| Charleson Comorbidity Score | < 0.0012 | ||||
| 0 | 1057 (73.3%) | 19828 (77.0%) | 8828 (75.1%) | 29713 (76.3%) | |
| 1 | 278 (19.3%) | 4486 (17.4%) | 2206 (18.8%) | 6970 (17.9%) | |
| 2+ | 107 (7.4%) | 1423 (5.5%) | 714 (6.1%) | 2244 (5.8%) | |
| Race3 | < 0.0012 | ||||
| Black | 185 (12.8%) | 2006 (7.8%) | 1108 (9.4%) | 3299 (8.5%) | |
| Other | 61 (4.2%) | 1501 (5.8%) | 562 (4.8%) | 2124 (5.5%) | |
| White | 1183 (82.0%) | 22054 (85.7%) | 10012 (85.2%) | 33249 (85.4%) | |
| Insurance status3 | < 0.0012 | ||||
| Medicare/medicaid/other government | 852 (59.1%) | 11308 (43.9%) | 5825 (49.6%) | 17985 (46.2%) | |
| Not insured | 38 (2.6%) | 1019 (4.0%) | 663 (5.6%) | 1720 (4.4%) | |
| Private insurance/managed care | 518 (35.9%) | 13117 (51.0%) | 5066 (43.1%) | 18701 (48.0%) | |
| Living location3 | < 0.0012 | ||||
| Metropolitan | 1164 (83.2%) | 20618 (82.2%) | 9142 (79.4%) | 30924 (81.4%) | |
| Rural | 30 (2.1%) | 548 (2.2%) | 295 (2.6%) | 873 (2.3%) | |
| Urban | 205 (14.7%) | 3916 (15.6%) | 2083 (18.1%) | 6204 (16.3%) | |
| Facility type3 | < 0.0012 | ||||
| Academic/research program | 540 (37.4%) | 9852 (38.3%) | 4536 (38.6%) | 14928 (38.3%) | |
| Community cancer program | 95 (6.6%) | 1453 (5.6%) | 711 (6.1%) | 2259 (5.8%) | |
| Comprehensive community cancer program | 562 (39.0%) | 9593 (37.3%) | 4538 (38.6%) | 14693 (37.7%) | |
| Integrated network cancer program | 193 (13.4%) | 3689 (14.3%) | 1451 (12.4%) | 5333 (13.7%) | |
| Facility geographic region3 | < 0.0012 | ||||
| Midwest | 343 (24.7%) | 6883 (28.0%) | 3528 (31.4%) | 10754 (28.9%) | |
| Northeast | 313 (22.5%) | 5040 (20.5%) | 2027 (18.0%) | 7380 (19.8%) | |
| South | 533 (38.3%) | 8522 (34.7%) | 3983 (35.4%) | 13038 (35.0%) | |
| West | 201 (14.5%) | 4142 (16.8%) | 1698 (15.1%) | 6041 (16.2%) |
- Citation: Soriano C, Bahnson HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V. Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma. World J Gastrointest Oncol 2022; 14(6): 1148-1161
- URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1148.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1148